Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track BLRX with free AI briefings, catalyst countdowns, and dilution alerts.

BLRX · BioLineRx Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13.1M Cash on Hand

14.5mo Cash Runway

Follow BLRX by email Get an email when BLRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BLRX, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Sep 2022 · Phase 2 · Results Expected · Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metasta
Registry primary completion date, not a results date
Jun 2022 · Phase 1 · Results Expected · Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy
Registry primary completion date, not a results date
Dec 2020 · Phase 3 · Active Trial · A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Gra
Registry primary completion date, not a results date
Nov 2020 · Phase 2 · Results Expected · Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG),
Registry primary completion date, not a results date
Mar 2016 · Phase 2 · Results Expected · Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patie
Registry primary completion date, not a results date
Jul 2015 · Phase 1 · Results Expected · A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobili
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
CYP-1020	Schizophrenia	Phase 2/3 · NCT01363349	Terminated
Motixafortide (BL-8040)	Multiple Myeloma	Phase 3 · NCT03246529	Active not recruiting
Equine Thymocyte Immune Globulin	Aplastic Anemia	Phase 2 · NCT02462252	Completed
Hydroxychloroquine	Hepatitis C	Phase 1/2 · NCT01833845	Terminated
Linagliptin	Gastric Adenocarcinoma or Gastroesophageal Junctio	Phase 1/2 · NCT03281369	Terminated
Methylprednisolone	Aplastic Anemia	Phase 2 · NCT02462252	Completed
Morphine	Acute Pain	Phase 1/2 · NCT00374881	Completed
PEGylated recombinant human hyaluronidas	Gastric Adenocarcinoma or Gastroesophageal Junctio	Phase 1/2 · NCT03281369	Terminated
Phenylephrine	Acute Pain	Phase 1/2 · NCT00374881	Completed
Sorbitol	Acute Pain	Phase 1/2 · NCT00374881	Completed
Tiragolumab	Gastric Adenocarcinoma or Gastroesophageal Junctio	Phase 1/2 · NCT03281369	Terminated
BL-7010	Celiac Disease	Phase 1/2 · NCT01990885	Completed
BL - 1020	Schizophrenia	Phase 2 · NCT00567710	Completed
BL 1020	Schizophrenia	Phase 2 · NCT00480571	Completed
BL-1020	Schizophrenia	Phase 2 · NCT00722176	Completed
BL-1020 10-30 mg	Schizophrenia	Phase 2 · NCT00722176	Completed

Also used in these trials (approved or third-party drugs, not BLRX's own candidates): Risperidone, Paclitaxel, Leucovorin, Oxaliplatin, Pembrolizumab, Ramucirumab, Ribavirin, Atezolizumab, Cyclosporine, Cisplatin, Cobimetinib, Perphenazine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BLRX holds $13.1M in cash and short-term investments and burns about $2.7M/quarter from operations, an estimated runway of 14.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Cash runway 14 months +18
ATM program on file since Jul 2025 +15
Shelf registration (F-3, Dec 2023) +10
Going-concern doubt in the latest 20-F +15Management has concluded that there is substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all. 20-F, Mar 2026
Share count +17% in a year +7
Raised after last reported balance sheet (Aug 2026) -10

Recent financing filings on SEC EDGAR:

Aug 31, 2026 · Registered direct / best-efforts offering · 424B5
Jul 25, 2025 · ATM program, up to $5M · 424B5
Jan 7, 2025 · Registered direct / best-efforts offering · 424B5
Apr 1, 2024 · Registered direct / best-efforts offering, $6M · 424B5
Dec 29, 2023 · Shelf registration, up to $250M · F-3

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BLRX files for a raise →

Get the full BLRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BLRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z